Total Funding
56
48
Total FundingVenture - Series Unknown raised
Growth Score
-17 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
86580
General Oncology is developing a pipeline of treatments for solid metastatic cancers and cancers of the blood.
- Gregg Goldstein: Chief Executive Officer and Chief Financial Officer
- Jeff Glazier: CEOPast Role: ProviderTech, Co-Founder
About the Company
General Oncology is developing a pipeline of treatments for solid metastatic cancers and cancers of the blood. They have a clinical trial underway for an investigational treatment for BRCA-related metastatic pancreatic cancer.
General Oncology is sponsoring a clinical trial (Clinical Trial GO-1) for its investigational treatment for BRCA-related
metastatic pancreatic cancer. The treatment involves two cycles of chemotherapy using melphalan, BCNU, vitamin B12b, and vitamin C, along with two stem cell transplants to reverse bone marrow suppression. The trial is currently open for enrollment.
